| Literature DB >> 34062163 |
Jianlin Ji1, Haitao Xiang2, Xu Lu1, Pingping Tan1, Rongrong Yang3, Ting Ye1, Zhuo Chen4, Dongjian Chen4, Haiyan He5, Jinliang Chen5, Yaoying Ma6, Chao Huang7.
Abstract
Innate immune activation has been shown to reduce the severity of nervous system disorders such as brain ischemia and traumatic brain damage. Macrophage-colony stimulating factor (M-CSF), a drug that is used to treat hematological system disease, is an enhancer of the innate immune response. In the present study, we evaluated the effect of M-CSF preconditioning on chronic social defeat stress (CSDS)-induced depression-like behaviors in mice. Results showed that a single M-CSF injection 1 day before stress exposure at the dose of 100 and 500 μg/kg, or a single M-CSF injection (100 μg/kg) 1 or 5 days but not 10 days before stress exposure prevented CSDS-induced depression-like behaviors in mice. Further analysis showed that a second M-CSF injection 10 days after the first M-CSF injection and a 2 × or 4 × M-CSF injections 10 days before stress exposure also prevented CSDS-induced depression-like behaviors. Molecular studies revealed that a single M-CSF injection prior to stress exposure skewed the neuroinflammatory responses in the brain in CSDS-exposed mice towards an anti-inflammatory phenotype. These behavioral and molecular actions of M-CSF were correlated with innate immune stimulation, as pre-inhibiting the innate immune activation by minocycline pretreatment (40 mg/kg) abrogated the preventive effect of M-CSF on CSDS-induced depression-like behaviors and neuroinflammatory responses. These results provide evidence to show that innate immune activation by M-CSF pretreatment may prevent chronic stress-induced depression-like behaviors via preventing the development of neuroinflammatory response in the brain, which may help to develop novel strategies for the prevention of depression.Entities:
Keywords: Innate immune activation; Macrophage-colony stimulating factor; Neuroinflammation; Prevention
Mesh:
Substances:
Year: 2021 PMID: 34062163 DOI: 10.1016/j.neuropharm.2021.108621
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250